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d El Libro de las Profecías, Christopher ColuPrevention of cardiovascular disease remains the “undis-
covered country” of cardiology, and is the focus of substantial
efforts in the domains of research and public policy (2,3).
The successful implementation of a cardiovascular disease
prevention strategy depends on 2 distinct aspects: 1) identiﬁ-
cation of the optimal target population; and 2) the appropriate
intervention for mitigating risk. To date, efforts aimed
at identifying at-risk populations for primary prevention
interventions have largely focused on patients with lipid
abnormalities, elevated high-sensitivity C-reactive protein (hs-
CRP), or diabetes mellitus. The natriuretic peptides, B-type
natriuretic peptide (BNP) and N-terminal pro–B-type natri-
uretic peptide (NT-proBNP), are increasingly recognized
as powerful tools for global risk prediction in cardiovascular
disease. While the initial discovery and development of these
biomarkers was focused on heart failure, it is now clear that
these markers can provide quantitative information about the
state of cardiovascular health across the spectrum of cardio-
vascular disease, ranging from the general population, to acute
and chronic ischemic heart disease, to heart failure (4–7).
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Natriuretic peptide levels across a broad range of values,
from slightly high to extremely elevated, are independently
predictive of future cardiovascular events and death (8).
Given that these markers are readily measured using widely
available and relatively inexpensive assays, their use to target
at-risk populations for primary prevention is inherently
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of natriuretic peptides to identify high-risk patients for
implementation of cardiovascular prevention interventions.
The recently published STOP-HF (St. Vincent’s Screening
To Prevent Heart Failure Study) trial randomized 1,374
asymptomatic patients with at least 1 risk factor for cardio-
vascular disease to BNP guided therapy versus usual care (9).
Those in the “BNP-guided arm” had plasma levels measured
annually, with specialized cardiology consultation for any
BNP values>50 pg/ml. After a mean follow-up period of 4.2
years, 8.7% of patients in the control group and 5.3% of
patients in the “biomarker” groupmet the primary endpoint of
asymptomatic left ventricular dysfunction or incident heart
failure (odds ratio: 0.55; 95% conﬁdence interval: 0.37 to
0.82; p  0.003). This issue of the Journal includes a report
of the results of a natriuretic peptide guided trial for primary
prevention of cardiovascular disease in patients with type 2
diabetes mellitus (10). The PONTIAC (NT-proBNP
Selected PreventiOn of cardiac eveNts in a populaTion of
dIabetic patients without A history of Cardiac disease) study
randomized 300 patients with type 2 diabetes mellitus, NT-
proBNP levels greater than >125 pg/ml and no known
cardiac disease, to a biomarker guided “intensiﬁed” group and
a “control group.” All patients were treated at diabetes care
units where guideline based therapies were pursued; those in
the “intensiﬁed” groupwere additionally treated at a cardiology
outpatient clinic for individualized up-titration of renin-
angiotensin system (RAS) antagonists and beta-blockers.
After 2 years, randomization to the biomarker-guided group
was associated with a remarkable 65% reduction in risk of the
primary endpoint of hospitalization or death due to cardiac
disease (p ¼ 0.04). The presumed mechanism for this treat-
ment effect was the use and intensity of neurohormonal
blockade:more patients in the intensiﬁed armwere usingRAS
antagonists and beta-blockers, and a greater percentagewere at
target doses.Notably, the event rates in the “intensiﬁed” group
were identical to patients who had NT-proBNP levels <125
pg/ml at study onset and were not included in the study, but
followed for cardiovascular outcomes.
Several aspects of these results deserve careful consider-
ation. The primary difference in process of care between the
2 treatment groups was specialized cardiology referral, and
guideline based care was mandated in both groups. It is
notable that the low percentage of patients in the control
arm on neurohormonal therapy remained largely unchanged
at 12 months despite fairly frequent outpatient follow-up
and a mandate for use and uptitration of guideline-based
therapies. Even without the help of biomarker guidance, one
can envision more aggressive use of therapies, especially
because intolerance seems to have been exceedingly rare,
with few reported side effects of therapy despite aggressive
up-titration. Also, it is notable that despite the major
reduction in cardiovascular risk, there were no differences in
measured blood pressures between the intervention and
control groups over the course of the study. These ﬁndings
raise the question of the mechanisms through which the
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a striking difference in outcomes. Finally, given that natri-
uretic peptide levels track closely with risk and are lowered
by neurohormonal antagonism in heart failure, it is unusual
that greater use of these therapies led to major improvements
in outcomes without effecting natriuretic peptide levels.
In considering how these results could be applied in
clinical care, several other questions remain: What is the
optimal target population? Are the ﬁndings unique to dia-
betics? Are certain therapeutic interventions such as RAS
antagonists preferred over others? Is use of this strategy cost-
effective and safe when applied more broadly? What are the
optimal cutpoints for natriuretic peptide levels? Finally,
given the relatively small number of events and short follow-
up period of the PONTIAC study, further validation of
these ﬁndings will be required.
How do we interpret the results of the PONTIAC study
in context of previous efforts in primary prevention of
cardiovascular disease? First, the magnitude of treatment
effect seen in PONTIAC is similar or greater to that of
related studies using similar interventions. Both the HOPE
(Heart Outcomes Prevention Evaluation) and STENO-2
studies previously showed substantial and similar risk reduc-
tion by using angiotensin-converting enzyme inhibitor
therapy in patients with diabetes, although these studies had
substantial proportions of patients with pre-existing cardio-
vascular disease (11,12). Second, PONTIAC follows on the
heels of the JUPITER (Justiﬁcation for the Use of Statins in
Primary Prevention: An Intervention Trial Evaluating
Rosuvastatin) trial that showed dramatic beneﬁts of using a
biomarker that signiﬁes subclinical cardiovascular disease to
guide therapy. JUPITER patients were apparently healthy,
without known diabetes, and normal low-density lipoprotein
cholesterol (<130 mg/dl), but elevated hs-CRP (>2.0 mg/l)
levels; statin use led to a 44% reduction in risk of major
cardiovascular events (13).
Are the results presented here enough to elevate natriuretic
peptides to the elite cadre of “post–low-density lipoprotein”
primary prevention biomarkers such as hs-CRP? Certainly,
the biological argument is sound. Clinically silent processes
in the cardiovascular system can gradually shift the homeo-
static balance from health to disease far before an index
cardiac event. Many of the pathologic processes known to be
precursors of cardiovascular disease can increase natriuretic
peptide levels. Cartesian reductionism suggests that identi-
fying and targeting these undesirable processes would
translate to improvements in cardiovascular health. Although
this seems self-evident, the literature is replete with examples
of primary prevention failures despite strong biologic plau-
sibility, such as hormone replacement therapy among others
(14). Clearly, the results of PONTIAC must be replicated
before they can be considered to be practice changing. To
underscore the relative size of the current study in the
primary prevention literature, there were more primary events
in the JUPITER (393) than total patients enrolled in the
PONTIAC study (300).The results of the PONTIAC study can be viewed in
light of a larger movement, particularly in heart failure,
toward “biomarker guided” therapy. The concept of titrating
therapy for chronic diseases based on a biomarker of disease
activity (such as HbA1C for diabetes or viral load for HIV) is
commonplace in medicine, but the results of applying this
paradigm to heart failure management have been mixed.
Several randomized trials have examined strategies of natri-
uretic peptide guided therapy for heart failure with varied
results; however, meta-analyses have suggested the possibility
of substantial clinical beneﬁts from this approach (15,16). A
large National Institutes of Health funded multicenter trial,
the GUIDE-IT (GUIDing Evidence Based Therapy
Using Biomarker Intensiﬁed Treatment in Heart Failure)
study (NCT01685840), is currently underway to provide
more deﬁnitive data on the efﬁcacy and safety of natriuretic
peptide guided therapy in heart failure. As this approach is
validated for advanced phenotypes, it seems likely that it will
continue to move “upstream” to progressively earlier stages of
disease.
Studies such as PONTIAC that use a single biomarker to
target or modify treatment are likely the tip of an iceberg
representing a shift toward a more nuanced view of the
diagnoses and treatment of cardiovascular disease. The last
decade has seen an exponential expansion in the landscape of
cardiovascular biomarkers, which now include innumerable
genetic variants, microRNAs, novel proteins, and metabo-
lites (17,18). A new view of disease explains it in terms of
aberrancies in interconnected biological networks, and
therapeutic interventions cause perturbations in the system’s
dynamic behavior in order to restore normal function from
a dysfunctional state (19). These responses can be predicted
based on integration of data from several sources: genetic,
biochemical, cellular, physiological, and clinical (20). Based
on this view of medicine, it seems naive to expect detailed
understanding of a complex disease process via measurement
of individual biomarkers alone. Indeed, the explosion of
increasingly robust and sensitive biomarkers will require an
ongoing reﬁnement of the very concept of disease and
prevention, as perturbations of the cardiovascular system are
recognizable and potentially amenable to intervention at far
earlier stages. Preliminary work using simpliﬁed multi-
marker strategies involving markers of various pathologic
processes (inﬂammation, ﬁbrosis, ischemia, myocardial wall
stress) have already been shown to improve risk prediction
over individual markers (21). It remains to be seen whether
such approaches may be helpful to target speciﬁc subsets of
the overall population at risk.
The results of the PONTIAC study suggest that
natriuretic peptide focused therapy may be an important new
avenue for targeting at-risk populations for primary preven-
tion strategies. Moving forward, a wide array of novel
molecular strategies will be able to detect risk at progressively
earlier stages of disease, and therapeutics could be tailored for
speciﬁc defects. Future studies will be required to reﬁne these
approaches such that they provide efﬁcacious, safe, and cost
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topher Columbus may have relied primarily on gut instinct,
contemporary cardiovascular prevention may be able to
depend on increasingly sophisticated Google maps.
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